TNBC is a heterogeneous collection of breast cancers lacking expression of oestrogen receptor (ER), progesterone receptor (PR), and HER2 amplification, the targets which form the basis for major first line therapies in cancer. This evidence concerns the gene ERBB2 and breast cancer.